Table 1.
Clinical Characteristics of the 21-Gene RS Population (n = 109)
| No. (%) | |
|---|---|
| Median age at diagnosis, years (range) | 52 (21-79) |
| Median primary tumor size, cm (range) | 3.1 (0.7-15.0) |
| Clinical node status | |
| N1/2 | 77 (71) |
| N0 | 18 (16) |
| Unknown | 14 (13) |
| ECOG status | |
| 0 | 58 (53) |
| 1 | 46 (42) |
| > 1 | 5 (5) |
| Tumor subtype | |
| HR positive/HER2 negative | 72 (66) |
| HR positive/HER2 positive | 20 (18) |
| HR negative/HER2 positive | 10 (9) |
| Triple negative | 7 (6) |
| Site of metastasis at first diagnosis | |
| Bone only | 50 (46) |
| Visceral only | 26 (24) |
| Both (bone and visceral) | 25 (23) |
| Other* | 8 (7) |
| No. of metastatic sites at first diagnosis | |
| Single organ | 65 (60) |
| > 1 organ | 44 (40) |
| First systemic treatment | |
| Chemotherapy | 26 (24) |
| Endocrine therapy | 52 (48) |
| Chemotherapy and endocrine therapy | 3 (3) |
| Chemotherapy plus trastuzumab | 20 (18) |
| Endocrine therapy plus trastuzumab | 6 (6) |
| RS distribution | |
| Low (< 18) | 22 (20) |
| Intermediate (18-30) | 29 (27) |
| High (≥ 31) | 50 (46) |
| Not available | 8 (7) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; RS, Recurrence Score.
*
Includes skin, pleura, contralateral axillary lymph nodes, mediastinal lymph nodes, paratracheal lymph nodes, endobronchial lymph nodes, hilar lymph nodes, and prepectoral lymph nodes.